Header links
Intranet
Donate now
image/svg+xml Map
Contact us

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of TAK-861 for the treatment of narcolepsy with cataplexy (Narcolepsy Type 1)

Contact
  • Protocol code: TAK-861-3001
  • EudraCT code: 2023-508465-32
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Romero Santo-Tomas, Odile
  • Research group:  Pneumologia
  • Service: Neurofisiologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase Ib, abierto y con dosis ascendentes para evaluar la seguridad, la tolerabilidad y la farmacocinética de PIT565 en participantes con lupus eritematoso sistémico

Contact
  • Protocol code: CPIT565B12101
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Cortes Hernandez, Josefina
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Fase I
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis

Contact
  • Protocol code: SRF201
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Guillen Del Castillo, Alfredo
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase IIa/b, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de amlitelimab subcutáneo en pacientes a

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Multicenter, Open-label, Long-term, Safety, Tolerability, andEfficacy Study of XEN1101 in Adults Diagnosed With Epilepsy.

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase IIb/III, multi-part, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of atacicept in subjects with IgA nephropathy (IgAN)

Contact
  • Protocol code: VT-001-0050
  • EudraCT code: 2020-004892-41
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Agraz Pamplona, Irene
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética del Vericiguat en pacientes pediátricos con insuficiencia cardíaca debido a disfunción sistólica sistémica del ventrículo izquierdo

Contact
  • Protocol code: MK-1242-036
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema circulatori
  • Principal investigator:  Rosés i Noguer, Ferran
  • Service: Cardiologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease on Stable Symptomatic Parkinson’s Disease Medication

Contact
  • Protocol code: BAN0805-201
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Hernández Vara, Jorge
  • Research group:  Malalties neurodegeneratives
  • Service: Neurologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de extensión de fase 3 abierto para evaluar la seguridad y la eficacia de MK-0616 en adultos con hipercolesterolemia

Contact
  • Protocol code: MK-0616-019
  • EudraCT code: No aplica
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Rial Lorenzo , Nuria
  • Research group:  Malalties infeccioses
  • Service: Medicina Interna
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Protocolo maestro de dos estudios en fase 3, independientes, aleatorizados y doble ciegos que comparan la eficacia y la seguridad de frexalimab (SAR441344) con teriflunomida en participantes adultos con formas recidivantes de esclerosis múltiple

Contact
  • Protocol code: EFC17919
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Montalban Gairín, Xavier
  • Research group:  Neuroimmunologia clínica
  • Service: Neuroimmunologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to